Zhang Z, Zhou M
Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Jun 12;47(6):571-575. doi: 10.3760/cma.j.cn112147-20240127-00059.
COVID-19 is caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and manifests primarily as acute lung injury with diffuse interstitial lung disease evident in imaging. Patients often present with clinical features similar to those of autoimmune diseases and share imaging, treatment and serological similarities with autoimmune-related interstitial lung diseases. The association between autoimmune abnormalities and post-COVID-19 pulmonary fibrosis is also recognized. This article provided a comprehensive review of the pathogenic mechanisms, clinical manifestations, and therapeutic interventions associated with autoimmune abnormalities induced by SARS-CoV-2 infection.
新型冠状病毒肺炎（COVID-19）由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染引起，主要表现为急性肺损伤，影像学上可见弥漫性间质性肺疾病。患者常表现出与自身免疫性疾病相似的临床特征，在影像学、治疗和血清学方面与自身免疫相关的间质性肺疾病存在相似之处。自身免疫异常与COVID-19后肺纤维化之间的关联也已得到认可。本文全面综述了与SARS-CoV-2感染所致自身免疫异常相关的发病机制、临床表现及治疗干预措施。
